Expanded Access to ANG1005 for Individual Patients

N/ANo Longer AvailableNCT02755987

Angiochem Inc

Overview

This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.

Study Type

EXPANDED_ACCESS

Conditions

Anaplastic Astrocytoma Anaplastic Oligodendroglioma Breast Cancer With Recurrent Brain Metastases Leptomeningeal Carcinomatosis

Interventions

ANG1005DRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Neurologically stable 2. Karnofsky performance status (KPS) ≥ 80 3. Adequate laboratory results Exclusion Criteria: 1. Radiotherapy within 3 months. 2. Evidence of significant intracranial hemorrhage 3. NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 Grade ≥ 2 neuropathy 4. Inadequate bone marrow reserve 5. Any evidence of severe or uncontrolled disease

Locations (2)

UC Irvine Health

Orange, California, United States

Univeristy of Texas Health Science Center in San Antonio

San Antonio, Texas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.